Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Dongchi Cai^1,2,#, Jialin Ji^3,#, Chunhui Yang^1,*, Hong Cai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152 - 30 December 2025

Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

Tao Zhu¹, Taofeng Wei¹, Mingdong Yang¹, Junjun Xu¹, Huifang Jiang¹, Wei He¹, Juyan Zheng^2,*, Haibin Dai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070180 - 30 December 2025

Abstract Background: Aberrant expression of transcription factors (TFs) is a key mechanism mediating tumor immune escape and therapeutic resistance. The involvement of E26 transformation-specific (ETS) family of TFs in immune regulation is not fully understood. The study aimed to elucidate the function of E-twenty-six variant 4 (ETV4) in tumor immune evasion and its potential as a predictive biomarker for immunotherapy in melanoma. Methods: The expression patterns of ETS family TFs were analyzed in melanoma and hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) was used to dissect the cellular expression and function of ETV4 in the tumor… More >

Kun Deng^1,2,3, Jianliang Huang^1,2,3, Danyang Li^2,3, Wei Gao^2,3, Minghua Wu^2,3,4,*, Mingsheng Lei^1,5,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069442 - 30 December 2025

Abstract Background: Glioblastoma (GBM) prognosis has seen little improvement over the past two decades. While immunotherapy has revolutionized cancer treatment, its impact on GBM remains limited. To characterize the evolving research landscape and identify future directions in GBM immunotherapy, we conducted a comprehensive bibliometric review. Methods: All literature related to immunotherapy in GBM from 1999 to 2024 was collected from the Web of Science Core Collection. CtieSpace and VOSviewer were used to conduct bibliometric analysis and visualize the data. Results: Bibliometric analysis identified 5038 publications authored by 23,335 researchers from 4699 institutions across 96 countries/regions, published in… More >

Xu Guo¹, Yanan Yu², Xiaolin Ma³, Yuanjie Cai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069274 - 30 December 2025

Abstract Background: Long non-coding RNAs (lncRNAs) act as epigenetic regulators for tumor hallmarks. This investigation sought to probe the carcinogenic trait of PAN3-AS1 across pan-cancer comprehensively. Methods: We studied the diagnostic and prognostic features and the immune landscape of PAN3-AS1 across pan-cancer by bioinformatics approaches. The hierarchical regulatory networks governing PAN3-AS1 expression in colon cancer were explored via chromatin immunoprecipitation, luciferase activity assays, and RNA immunoprecipitation, etc. We screened drugs sensitive to WAP four-disulfide core domain 13 (WFDC13) by virtual screening and molecular docking. Results: Single-cell transcriptomics demonstrated that a variety of immune populations abnormally expressed PAN3-AS1… More >

Shujie Yin¹, Zong Li¹, Wen-Bin Ou^1,2,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069049 - 30 December 2025

Abstract Ferroptosis is an iron-dependent, excessive lipid peroxidation-driven form of regulated cell death. The core mechanisms of ferroptosis include lipid peroxidation cascade, System X_c⁻-glutathioneglutathione peroxidase 4 axis, iron and lipid metabolism chaos, the NAD(P)Hferroptosis suppressor protein 1—ubiquinone axis, and GTP cyclohydrolase 1 tetrahydrobiopterin-dihydrofolate reductase axis. Cuproptosis is triggered by copper ions and involves ferredoxin 1-mediated aggregation of lipoylated proteins, differing fundamentally from ferroptosis. Both ferroptosis and cuproptosis exhibit dual roles (promote or inhibit) in cancers. And the sensitivity of different cancer types to ferroptosis varies, which may depend on special metabolic signatures (e.g., E-cadherin loss causes epithelial–mesenchymal More > Graphic Abstract

Anushka Ghosh, Maria J. D’Amico, Yash B. Shah, Whitney R. Smith, Mihir S. Shah, Costas D. Lallas, Alana M. Murphy^*

Canadian Journal of Urology, Vol.32, No.6, pp. 627-632, 2025, DOI:10.32604/cju.2025.067575 - 30 December 2025

Abstract Background: Genitourinary syndrome of menopause (GSM) is a highly prevalent, underdiagnosed condition that can significantly impair quality of life (QoL). This study evaluates real-world treatment trends for GSM to better understand current management practices and highlight ongoing gaps in care. The background is in a different font than the rest of the abstract. Methods: We queried the TriNetX database for patients with a diagnosis of postmenopausal atrophic vaginitis (ICD N95.2) and treatment information from 2004–2024. A combination of RxNorm and International Classification of Diseases-10 (ICD) codes was used to classify disease and treatment type, including… More >

Jordan L. Mendelson^1,*, Jordan Kassab¹, Phillip Westbrook¹, Katie Yang², Anthony Corcoran¹

Canadian Journal of Urology, Vol.32, No.6, pp. 673-676, 2025, DOI:10.32604/cju.2025.063770 - 30 December 2025

Abstract Stereotactic body radiotherapy (SBRT) for prostate cancer is a generally well-tolerated treatment but can rarely lead to complications such as fistula formation. We report a 69-year-old male on maintenance ibrutinib for chronic lymphocytic leukemia who developed a fistula between his bladder and vas deferens in the setting of ascending scrotal infection. Despite his prior history of SBRT, the fistula was successfully treated with minimally invasive measures. A combination of abscess debridement, urinary diversion, and broad-spectrum antibiotics helped to achieve fistula resolution. The unique presentation described herein highlights the importance of early aggressive intervention for source More >

Abdul Baseet Arham¹, John M. Rieth², Michael A. O’Donnell^3,*

Canadian Journal of Urology, Vol.32, No.6, pp. 605-620, 2025, DOI:10.32604/cju.2025.063632 - 30 December 2025

Abstract Background: Genitourinary (GU) sarcomas are rare soft tissue malignancies, comprising around 2% of all GU cancers. Due to their rarity, limited data exist on optimal management and long-term outcomes. This study presents a 25-year single-institution experience, evaluating clinical presentation, treatment strategies, and survival outcomes, aims to identify trends over time and potential predictors of prognosis. Methods: A retrospective review was conducted of patients aged ≥18 years diagnosed with GU sarcomas at the University of Iowa Hospitals and Clinics (1998–2023). Data on tumor subtype, staging, histopathology, treatment modalities, and survival outcomes were analyzed. Kaplan-Meier analysis estimated… More >

Chang-Eui Hong^1,2,3, Su-Yun Lyu^1,2,3,*

BIOCELL, Vol.49, No.12, pp. 2377-2397, 2025, DOI:10.32604/biocell.2025.072360 - 24 December 2025

Abstract Objective: Triple-negative breast cancer (TNBC) remains a major therapeutic challenge with limited treatment options and poor prognosis. This study aimed to investigate the synergistic anticancer effects of doxorubicin (DOX) combined with Viscum album L. var. coloratum agglutinin (VCA) and to elucidate the underlying molecular mechanisms in TNBC cells. Methods: This study evaluated the synergistic effects and mechanisms of doxorubicin (DOX) and Viscum album L. var. coloratum agglutinin (VCA) combination in MDA-MB231 TNBC cells. Cell viability, oxidative stress markers, apoptosis-related proteins, cell migration, and proliferative recovery were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, superoxide dismutase (SOD) and nitric oxide… More >